Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
Who will be the biggest pharma players in orphan drugs?New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Share XWho will be the biggest pharma players in orphan drugs?https://pharmaphorum.com/views-analysis-sales-marketing/who-will-be-the-biggest-pharma-players-in-orphan-drugs/
Removing logistical barriers to improve clinical trial retentionWe all know how long and arduous the clinical trial road is for sites and sponsors – but Share XRemoving logistical barriers to improve clinical trial retentionhttps://pharmaphorum.com/views-analysis-patients/removing-logistical-barriers-to-improve-clinical-trial-retention/
Rova-T: the story of AbbVie’s multi-billion dollar failureRichard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Share XRova-T: the story of AbbVie’s multi-billion dollar failurehttps://pharmaphorum.com/r-d/views-analysis-r-d/rova-t-the-story-of-abbvies-multi-billion-dollar-failure/
Delivering innovative therapies with close industry-NHS partnershipsIt was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Share XDelivering innovative therapies with close industry-NHS partnershipshttps://pharmaphorum.com/r-d/views-analysis-r-d/delivering-innovative-therapies-with-close-industry-nhs-partnerships/
The challenges of measuring dementiaOxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, Share XThe challenges of measuring dementiahttps://pharmaphorum.com/views-and-analysis/the-challenges-of-measuring-dementia/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Towards patient centricity: PfizerIn a new series Amanda Barrell looks at how different companies are turning patient centricity into a reality. Share XTowards patient centricity: Pfizerhttps://pharmaphorum.com/views-and-analysis/towards-patient-centricity-pfizer/
